In the last trading session, 84.27 million shares of the Cyclo Therapeutics Inc (NASDAQ:CYTH) were traded, and its beta was -0.57. Most recently the company’s share price was $1.19, and it changed around $0.42 or 54.55% from the last close, which brings the market valuation of the company to $34.05M. CYTH currently trades at a discount to its 52-week high of $1.92, offering almost -61.34% off that amount. The share price’s 52-week low was $0.55, which indicates that the current value has risen by an impressive 53.78% since then. We note from Cyclo Therapeutics Inc’s average daily trading volume that its 10-day average is 8.5 million shares, with the 3-month average coming to 45.40K.
Cyclo Therapeutics Inc stock received a consensus recommendation rating of Hold, based on a mean score of 3.00. If we narrow it down even further, the data shows that 0 out of 3 analysts rate the stock as a Sell; another 0 rate it as Overweight. Among the rest, 2 recommended CYTH as a Hold, whereas 1 deemed it a Buy, and 0 rated it as Underweight. Cyclo Therapeutics Inc is expected to report earnings per share of 0 for the current quarter.
Cyclo Therapeutics Inc (NASDAQ:CYTH) trade information
Instantly CYTH has showed a green trend with a performance of 54.55% at the end of last trading. The performance over the last five days has remained in the green territory. The rise to weekly highs of 1.4500 on recent trading dayincreased the stock’s daily price by 17.93%. The company’s shares are currently up 101.69% year-to-date, but still up 54.55% over the last five days. On the other hand, Cyclo Therapeutics Inc (NASDAQ:CYTH) is 83.08% up in the 30-day period. We can see from the shorts that 0.11 million shares have been sold at a short interest cover period of 3.82 day(s).
The consensus price target as assigned by Wall Street analysts is $0.95, which translates to bulls needing to decrease their stock price by -25.26% from its current value. Analyst projections state that CYTH is forecast to be at a low of $0.95 and a high of $0.95.
Cyclo Therapeutics Inc (CYTH) estimates and forecasts
The year-over-year growth rate is expected to be -10.23%, down from the previous year.
Consensus estimates provided by 3 financial analysts predict the company will bring in an average of 322k in revenue for the current quarter. 2 analysts expect Cyclo Therapeutics Inc to make 150k in revenue for the current ending quarter. The company’s sales for the same quarters a year ago were 311.4k and 202.45k respectively. Analysts predict that the company’s current quarter sales will jump, forecast at 3.40%. Forecasts for the next quarter put sales growth at -25.91%.
Looking at the company’s year-over-year earnings, the past five years showed a negative earnings growth rate of -88.22%.
CYTH Dividends
Cyclo Therapeutics Inc’s next quarterly earnings report is expected to be released in March.
Cyclo Therapeutics Inc (NASDAQ:CYTH)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 40.08% of Cyclo Therapeutics Inc shares, and 13.17% of them are in the hands of institutional investors. The stock currently has a share float of 21.98%.
